The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
High-Dose Resveratrol Treatment for 2 Weeks Inhibits Intestinal and Hepatic Lipoprotein Production in Overweight/Obese Men
Abstract
Objective—: Overproduction of hepatic apolipoprotein B (apoB)-100 containing very low-density lipoprotein particles and intestinal apoB-48 containing chylomicrons contributes to hypertriglyceridemia seen in conditions such as obesity and insulin resistance. Some, but not all, preclinical and clinical studies have demonstrated that the polyphenol resveratrol ameliorates insulin resistance and hypertriglyceridemia. Here, we assessed intestinal and hepatic lipoprotein turnover, in humans, after 2 weeks of treatment with resveratrol (1000 mg daily for week 1 followed by 2000 mg daily for week 2) or placebo. Approach and Results—: Eight overweight or obese individuals with mild hypertriglyceridemia were studied on 2 occasions, 4 to 6 weeks apart, after treatment with resveratrol or placebo in a randomized, double-blinded, crossover study. Steady-state lipoprotein kinetics was assessed in a constant fed state with a primed, constant infusion of deuterated leucine. Resveratrol treatment did not significantly affect insulin sensitivity (homeostasis model of assessment of insulin resistance), fasting or fed plasma triglyceride concentration. Resveratrol reduced apoB-48 production rate by 22% ( P =0.007) with no significant effect on fractional catabolic rate. Resveratrol reduced apoB-100 production rate by 27% ( P =0.02) and fractional catabolic rate by 26% ( P =0.04). Conclusions—: These results indicate that 2 weeks of high-dose resveratrol reduces intestinal and hepatic lipoprotein particle production. Long-term studies are needed to evaluate the potential clinical benefits of resveratrol in patients with hypertriglyceridemia, who have increased concentrations of triglyceride-rich lipoprotein apoB-100 and apoB-48. Clinical Trial Registration—: URL: www.clinicaltrials.gov . Unique identifier: NCT01451918.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors found no changes in insulin sensitivity and triglyceride concentration, but they observed a significant reduction in apoB-48 and apoB-100, which are lipoprotein particles produced by the intestine and liver, respectively [39].”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [39]
In the citing paper
“The authors found no changes in insulin sensitivity and triglyceride concentration, but they observed a significant reduction in apoB-48 and apoB-100, which are lipoprotein particles produced by the intestine and liver, respectively [39].”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Li, Y., Xu, S., Mihaylova, M. M., Zheng, B., Hou, X., Jiang, B., Park, O., Luo, Z., Lefai, É., Shyy, J. Y.-J., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.009 · Cited by 1,840
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases
Park, S. J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., Ke, H., Rehmann, H., Taussig, R., Brown, A. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.017 · Cited by 1,370
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320
Heilbronn, L. K., de Jonge, L., Frisard, M. I., DeLany, J. P., Larson-Meyer, D. E., Rood, J., Nguyen, T., Martin, C. K., Volaufova, J., Most, M. M., et al. (2006) · JAMA · doi:10.1001/jama.295.13.1539 · Cited by 969
Long-Term Calorie Restriction Is Highly Effective in Reducing the Risk for Atherosclerosis in Humans
Fontana, L., Meyer, T. E., Klein, S., & Holloszy, J. O. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308291101 · Cited by 902
Flagged first, then by citations
Research works printed but not linked: 1
- Veilleux A, Grenier E, Carpentier A, Richard D, Levy E. Alterations in intestinal insulin signaling in obese subjects and their effect on lipid and lipoprotein metabolism (abstract). Diabetes. 2012;61:A15.
Cited by
Sorted by citations
Items 101–102 of 102
Translating Resveratrol Research: A Systematic Review on Patents and Clinical Trials (2000–2025)
Kaurav, M., Ghai, R., Pal, N., & Nagarajan, K. (2026) · The Open Biotechnology Journal · doi:10.2174/0118740707407791260409045456
Simental‐Mendía, L. E., Arce‐Quiñones, M., & Sahebkar, A. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104866
Metadata
- Authors
- Dash, S., Xiao, C., Morgantini, C., Szeto, L., & Lewis, G. F.
- Affiliations
- Scuola Superiore Sant'Anna (IT)
- Corresponding author
- Dash, Satya
- Xiao, Changting
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2013-12
- Volume
- 33
- Issue
- 12
- Pages
- 2895-2901
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2165712074
- Cited by
- 102
- References
- 33
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 6 · 2018: 11 · 2017: 12 · 2016: 13 · 2015: 15 · 2014: 10
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- resveratrol, hypertriglyceridemia, apolipoprotein B-100, apolipoprotein B-48, VLDL, chylomicrons, lipoprotein production, lipoprotein turnover, fractional catabolic rate, obesity, insulin resistance, triglyceride-rich lipoproteins
- MeSH terms
- Resveratrol, Adult, Analysis of Variance, Hypolipidemic Agents, Double-Blind Method, Drug Administration Schedule, Humans, Insulin Resistance, Intestinal Mucosa, Intestines, Lipoproteins, Liver, Male, Middle Aged, Obesity, Ontario, Stilbenes, Time Factors, Triglycerides, Hypertriglyceridemia, Biomarkers, Treatment Outcome, Cross-Over Studies, Overweight, Apolipoprotein B-48, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
